Drug interactions
Nivolumab + Ponesimod
Severity: Moderate
Nivolumab and Ponesimod: moderate interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Ponesimod reduces circulating lymphocytes, while nivolumab alters immune regulation and can cause immune-related adverse events that are often treated with immunosuppression. Together they may make immune responses unpredictable and could raise infection risk or blunt antitumor immunity. Clinical data on the combination are limited.
What this interaction means in plain words
Nivolumab and Ponesimod can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken.
Nivolumab belongs to Oncology; Ponesimod belongs to Central Nervous System.
Why it happens
Ponesimod sequesters lymphocytes in lymphoid tissue via S1P receptor modulation, which may counteract the T-cell activation sought with PD-1 blockade.
What to do
Avoid starting ponesimod during checkpoint inhibitor therapy unless clearly needed. If combined, monitor for infections and lymphocyte counts and reassess the oncologic benefit.
What to ask your pharmacist
- Should I take them at different times of day?
- Does the dose of either medicine need to change?
- Is there anything I should avoid, such as alcohol or certain foods, while on both?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Nivolumab and Ponesimod, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 14 days on the web. No card needed.
Other interactions of Nivolumab
- Nivolumab + Thalidomide Major
- Dexamethasone-tobramycin + Nivolumab Moderate
- Dexamethasone + Nivolumab Moderate
- Efgartigimod / hyaluronidase sc + Nivolumab Moderate
- Efgartigimod alfa + Nivolumab Moderate
- Nivolumab + Rozanolixizumab Moderate
Other interactions of Ponesimod
- Fingolimod + Ponesimod Contraindicated
- Ponesimod + Siponimod Contraindicated
- Amiodarone + Ponesimod Major
- Amisulpride + Ponesimod Major
- Anagrelide + Ponesimod Major
- Anti-thymocyte + Ponesimod Major
Frequently asked questions
Can I take Nivolumab with Ponesimod?
MediHelp rates the interaction as moderate. Nivolumab and Ponesimod can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken. Ponesimod reduces circulating lymphocytes, while nivolumab alters immune regulation and can cause immune-related adverse events that are often treated with immunosuppression. Together they may make immune responses unpredictable and could raise infection risk or blunt antitumor immunity. Clinical data on the combination are limited.
How serious is the interaction between Nivolumab and Ponesimod?
MediHelp rates it moderate, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Avoid starting ponesimod during checkpoint inhibitor therapy unless clearly needed. If combined, monitor for infections and lymphocyte counts and reassess the oncologic benefit.
What other medicines interact with Nivolumab?
MediHelp also lists interactions of Nivolumab with, for example, Thalidomide, Dexamethasone-tobramycin, Dexamethasone. The full list is on the Nivolumab page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
